---
title: Gatifloxacin + Loteprednol etabonate
description: >-
  Gatifloxacin + Loteprednol etabonate is prescribed for the treatment of
  steroid-responsive inflammatory ocular conditions where superficial bacterial
  ocular infection or a risk of bacterial ocular infection exists. This includes
  post-operative inflammation and infection following ocular surgery. ...
is_banned: false
lastModified: '2025-09-22T17:22:09.287Z'
faqs:
  - q: >-
      What is the recommended dosage for Gatifloxacin + Loteprednol etabonate?**


      **A:**  1-2 drops in the affected eye(s) every 4-6 hours. Initially,
      during the first 24-48 hours, the frequency can be increased up to every
      1-2 hours.
    a: >-
      A:**  1-2 drops in the affected eye(s) every 4-6 hours. Initially, during
      the first 24-48 hours, the frequency can be increased up to every 1-2
      hours.
  - q: >-
      What are the common side effects?**


      **A:** Blurred vision, eye irritation, eye pain, redness, tearing, foreign
      body sensation.
    a: >-
      A:** Blurred vision, eye irritation, eye pain, redness, tearing, foreign
      body sensation.
  - q: >-
      What are the contraindications?**


      **A:** Hypersensitivity, herpes simplex keratitis, fungal or mycobacterial
      eye infections.
    a: >-
      A:** Hypersensitivity, herpes simplex keratitis, fungal or mycobacterial
      eye infections.
  - q: >-
      Can this be used in children?**


      **A:** Safety and efficacy have not been established for children below
      one year old. For children one year and older, follow adult dosing.
    a: >-
      A:** Safety and efficacy have not been established for children below one
      year old. For children one year and older, follow adult dosing.
  - q: >-
      Can pregnant or breastfeeding women use this medication?**


      **A:**  Pregnancy Category C – use only if the benefit outweighs the
      risk.  Caution advised during breastfeeding.
    a: >-
      A:**  Pregnancy Category C – use only if the benefit outweighs the risk. 
      Caution advised during breastfeeding.
  - q: >-
      How long should treatment continue?**


      **A:**  As directed by the physician. Do not discontinue prematurely, even
      if symptoms improve.
    a: >-
      A:**  As directed by the physician. Do not discontinue prematurely, even
      if symptoms improve.
  - q: |-
      Are there any drug interactions?**

      **A:** No specific drug interactions are documented.
    a: 'A:** No specific drug interactions are documented.'
  - q: >-
      What should be monitored during treatment?**


      **A:** Intraocular pressure, visual acuity, and any signs of worsening
      infection.
    a: >-
      A:** Intraocular pressure, visual acuity, and any signs of worsening
      infection.
  - q: |-
      Can contact lenses be worn during treatment?**

      **A:** Contact lens wear should be avoided during treatment.
    a: 'A:** Contact lens wear should be avoided during treatment.'
---
## **Usage**

Gatifloxacin + Loteprednol etabonate is prescribed for the treatment of steroid-responsive inflammatory ocular conditions where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. This includes post-operative inflammation and infection following ocular surgery.  It is also used for inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, iritis, and cyclitis.

**Pharmacological Classification:**

* Gatifloxacin: Fluoroquinolone antibiotic
* Loteprednol etabonate: Corticosteroid

**Mechanism of Action:**

This combination drug works through two distinct mechanisms:

* **Gatifloxacin:** Inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, and repair, leading to bacterial cell death.
* **Loteprednol etabonate:**  Binds to glucocorticoid receptors, suppressing the inflammatory response by inhibiting the release of arachidonic acid, a precursor to inflammatory mediators like prostaglandins and leukotrienes.


## **Alternate Names**

There are no widely recognized alternate names for the combination itself. The individual components are sometimes referred to as:

* **Gatifloxacin:**  Gatifloxacina (Spanish), Gatifloxacine (French)
* **Loteprednol etabonate:**  Loteprednol etabonato (Spanish), Loteprednol etabonate (French)

**Brand Names:**  Lotegate, Lotepro G, Zypred, Loterex G, Vatiflo-LP


## **How It Works**

**Pharmacodynamics:**

* **Gatifloxacin:** Bactericidal action against a broad spectrum of gram-positive and gram-negative bacteria commonly implicated in ocular infections.
* **Loteprednol etabonate:** Anti-inflammatory and immunosuppressive effects, reducing redness, swelling, pain, and itching associated with ocular inflammation.

**Pharmacokinetics:**

* **Absorption:**  Following topical ophthalmic administration, both drugs achieve therapeutic concentrations in ocular tissues.  Systemic absorption is minimal.
* **Metabolism:** Primarily hepatic metabolism for both drugs, though information on specific pathways for Loteprednol etabonate ophthalmic is limited.
* **Elimination:** Gatifloxacin is primarily excreted renally. Loteprednol etabonate ophthalmic elimination pathways are not well-characterized due to its low systemic absorption.

**Mode of Action:**

* **Gatifloxacin:** Inhibits bacterial DNA gyrase and topoisomerase IV, ultimately leading to bacterial cell death.
* **Loteprednol etabonate:** Binds to glucocorticoid receptors, inhibiting inflammatory mediator production.

**Receptor Binding/Enzyme Inhibition:**

* **Gatifloxacin:** Inhibits DNA gyrase and topoisomerase IV.
* **Loteprednol etabonate:**  Binds to glucocorticoid receptors.


## **Dosage**



### **Standard Dosage**

#### **Adults:**

Instill one or two drops into the affected eye(s) every four to six hours. During the initial 24 to 48 hours, dosing may be increased to every one to two hours.

#### **Children:**

Safety and efficacy have not been established in children below one year of age.  For children 1 year and older, follow adult dosing.


#### **Special Cases:**

* **Elderly Patients:**  No specific dosage adjustments are typically necessary.
* **Patients with Renal Impairment:** No dose adjustment data are available.  Use with caution.
* **Patients with Hepatic Dysfunction:** No dose adjustment data are available.  Use with caution.
* **Patients with Comorbid Conditions:** Exercise caution in patients with glaucoma, herpes simplex keratitis, fungal infections, mycobacterial eye infections, or conditions predisposing to corneal perforation.


### **Clinical Use Cases**

Dosage recommendations for specific clinical use cases generally follow the standard adult dosing, with adjustments as needed based on the severity of inflammation and infection.



### **Dosage Adjustments**

Dose modifications should be guided by clinical response and tolerance.  No specific guidelines exist for dosage adjustments based on renal/hepatic dysfunction, metabolic disorders, or genetic polymorphisms.


## **Side Effects**


### **Common Side Effects**

Blurred vision, eye irritation, eye pain, eye redness, tearing, foreign body sensation, itching, stinging, photophobia, dry eye, bad taste.


### **Rare but Serious Side Effects**

Elevated intraocular pressure, cataracts, secondary ocular infections (including herpes simplex), corneal perforation, vision changes.


### **Long-Term Effects**

Prolonged use can increase the risk of glaucoma, cataracts, and secondary infections.

### **Adverse Drug Reactions (ADR)**

Severe allergic reactions (rare), characterized by rash, itching, swelling, difficulty breathing.


## **Contraindications**

Hypersensitivity to gatifloxacin, loteprednol etabonate, other quinolones, or corticosteroids.  Most viral diseases of the cornea and conjunctiva (e.g., herpes simplex keratitis).  Fungal and mycobacterial infections of the eye.  


## **Drug Interactions**

No specific drug interactions are well documented.  Separate administration of multiple eye medications by at least 5-10 minutes.


## **Pregnancy and Breastfeeding**

Pregnancy Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.  Caution should be exercised when administering to a nursing woman.


## **Drug Profile Summary**

* **Mechanism of Action:** Gatifloxacin: Inhibits bacterial DNA gyrase and topoisomerase IV. Loteprednol etabonate:  Suppresses inflammation by inhibiting arachidonic acid release.
* **Side Effects:** Blurred vision, eye irritation, eye pain, elevated IOP, cataracts, secondary infections.
* **Contraindications:** Hypersensitivity, viral keratitis, fungal/mycobacterial eye infections.
* **Drug Interactions:** No specific interactions documented.
* **Pregnancy & Breastfeeding:** Pregnancy Category C; use with caution during breastfeeding.
* **Dosage:** 1-2 drops every 4-6 hours, initially up to every 1-2 hours.
* **Monitoring Parameters:** Intraocular pressure, visual acuity, signs of infection.



## **Popular Combinations**

This combination is itself a popular and effective treatment for ocular inflammation and infection. No other specific drug combinations are routinely recommended in conjunction with this medication.



## **Precautions**

Monitor intraocular pressure with prolonged use.  Avoid contact lens wear during treatment.  Watch for signs of secondary infection.  Exercise caution in patients with glaucoma or a history of herpes simplex keratitis.


## **FAQs (Frequently Asked Questions)**

### **Q1: What is the recommended dosage for Gatifloxacin + Loteprednol etabonate?**

**A:**  1-2 drops in the affected eye(s) every 4-6 hours. Initially, during the first 24-48 hours, the frequency can be increased up to every 1-2 hours.

### **Q2: What are the common side effects?**

**A:** Blurred vision, eye irritation, eye pain, redness, tearing, foreign body sensation.

### **Q3:  What are the contraindications?**

**A:** Hypersensitivity, herpes simplex keratitis, fungal or mycobacterial eye infections.

### **Q4: Can this be used in children?**

**A:** Safety and efficacy have not been established for children below one year old. For children one year and older, follow adult dosing.

### **Q5: Can pregnant or breastfeeding women use this medication?**

**A:**  Pregnancy Category C – use only if the benefit outweighs the risk.  Caution advised during breastfeeding.

### **Q6:  How long should treatment continue?**

**A:**  As directed by the physician. Do not discontinue prematurely, even if symptoms improve.

### **Q7:  Are there any drug interactions?**

**A:** No specific drug interactions are documented.

### **Q8: What should be monitored during treatment?**

**A:** Intraocular pressure, visual acuity, and any signs of worsening infection.

### **Q9:  Can contact lenses be worn during treatment?**

**A:** Contact lens wear should be avoided during treatment.

